2016 Update
Key population
Guidelines
Key Populations
Inter-Agency Task Team on HIV and Young People
Guidance Brief
Accessed: 09.11.2019
Science / People / Progress
Accessed: 12.11.2019
Guidelines
June 2017
HIV strategic information for impact
HIV patient monitoring and case surveillance
HIV-related advocacy evaluation training for civil society organisations
Strengthening Community responses to HIv Treatment and Prevention
Advocacy achievements of the bridging the gaps global partners
Accessed: 17.11.2019
Accountability for the global health sector strategies, 2016–2021
WHO/CDS/HIV/19.7
UNAIDS | 2016–2021 Strategy
Accessed: 20.11.2019
Technical Update
HIV Treatment
July 2017
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Experiences from Indonesia, Kenya, Uganda and Ukraine